Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Gatorgunk
Gatorgunk Feb. 23 at 5:39 AM
$CAPR $RHHBY is definitely going to attempt to buy $CAPR
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 21 at 9:05 PM
$RHHBY
0 · Reply
briefingcom
briefingcom Feb. 20 at 1:52 PM
$RHHBY: Roche Hldg: FDA approves Genentch's Venclexta plus acalabrutinib for first-line CLL https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260220050540RHHBY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Quantumup
Quantumup Feb. 20 at 1:39 PM
Needham⬇️ $OCUL's PT to $18 from $20, reiterated at Buy and said, OCUL shares have been under pressure following SOL-1 topline data (see 2/17/26 note for recap), despite meeting key endpts. $REGN $EYPT $RHHBY KOD $SRZN Needham went on to say: Weakness was driven by a narrower-than-expected efficacy gap (~18%Δ) on vision maintenance due to an Eylea outperformance, as well as incidents of (mostly minor) AEs. SOL-1 results came short of investor expectations, but should still support FDA approval with a superiority label vs. Eylea with data supporting Q6M-Q12M dosing. These are key differentiating attributes vs. current pdts and those in development that should facilitate wide usage of Axpaxli. We view the recent valuation reset, which began prior to SOL-1 results, as overdone, and maintain our Buy rating and adjust our $ PT to $18 (from $20) to account for slightly lower Axpaxli peak sales.
1 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 19 at 2:18 PM
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development $OTLC $DNLI $RHHBY $ALNY $WVE https://ibn.fm/sRoMP
0 · Reply
Quantumup
Quantumup Feb. 19 at 1:38 PM
Cantor🏁 $SRZN Overweight/$40 $EYPT $OCUL $REGN $RHHBY KOD FDMT Cantor said: We are initiating coverage of SRZN at Overweight with a $40 price target. SRZN is a leader in Wnt biology, with foundational IP based on early work developing Wnt agonists and more recently advancing complex molecules towards the clinic in retinal diseases (Wnt/VEGF and Wnt/VEGF/IL-6 multi-functional molecules). SZN-8141 in both DME (PoS: 35%) and nAMD (PoS 20%). At a net price comparable with precedent VEGF products (~$14.5K per year), the resulting peak global probability-adjusted net sales are $895M for DME ($2.6B unadjusted) and $614M for nAMD ($3.1B unadjusted). Our $40 price target is based on our DCF, which utilizes a 15% discount rate and 2% terminal growth rate. We use ~25M fully diluted shares in our DCF compared to~8.6M basic shares as of 3Q25. 25M includes shares from the 2nd tranche of the PIPE (expected by Oct 31 2026) and adjusts the number of PIPE warrants using treasury stock method.
0 · Reply
AItrad
AItrad Feb. 18 at 1:40 PM
$OCUL A lot of people here are missing the point. SOL1 hit its primary endpoint agreed upon with the FDA to have a SUPERIORITY label. It will get approved no matter what the Eylea did in the study. This is the important thing: THE VALUE OF A SUPERIOR LABEL IS PRICELESS IN MARKETING. The marketing is going to be relentless. Think about the amount of Vabysmo and Eylea HD commercials you see now. Why so many? because they work on the patients. If these same patients see a commercial for Axpali that says it is THE ONLY MEDICINE EVER FOUND TO BE SUPERIOR TO EYLEA. A NEXT GENERATION MEDICATION THAT IS BETTER! BASED ON A PHASE 3 CLINICAL TRIAL, they will DEMAND the drug. It doesn’t matter how the trial was designed, the patients don’t understand the nuances, they just want the SUPERIOR drug. $EYPT won’t have that, $REGN won’t have that, $RHHBY won’t have that label. Only $OCUL. This is worth more than anything.
6 · Reply
scotttrader213
scotttrader213 Feb. 17 at 2:29 PM
$RHHBY moving much higher.
0 · Reply
free2dream
free2dream Feb. 17 at 1:27 PM
$SRPT move to $25 this week is in play, the quarter will be in $400M range, I would not be surprised to next quarter to return to the usual $600M range. Earnings next week, $RHHBY should snatch this while sub $2B market cap. They can assign easily 300-500% premium $XBI
2 · Reply
Watchthosestocks
Watchthosestocks Feb. 16 at 10:30 PM
$OCUL These results cover a "first to market" treatment with dominance potential in the same market that $SNY, $RHHBY, $MRK, and $BAYRY are all trying to get into or improve on. OCUL has highly likely showing of dominance from the results given the study is specifically designed to show "superiority" and all indications are positive — from a Tuesday AM announcement time preset, along with the speed of result release (no extra time taken to sugar coat something bad), interesting new job postings relating to sales/new products, special arrangements with the FDA to ensure study success, offers already from SNY, and the study design itself-(it's either superior or not) If it wasn't superior, it's very likely they would report the data at this time and in this way Good luck tomorrow
0 · Reply
Latest News on RHHBY
No data available.
Gatorgunk
Gatorgunk Feb. 23 at 5:39 AM
$CAPR $RHHBY is definitely going to attempt to buy $CAPR
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 21 at 9:05 PM
$RHHBY
0 · Reply
briefingcom
briefingcom Feb. 20 at 1:52 PM
$RHHBY: Roche Hldg: FDA approves Genentch's Venclexta plus acalabrutinib for first-line CLL https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260220050540RHHBY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Quantumup
Quantumup Feb. 20 at 1:39 PM
Needham⬇️ $OCUL's PT to $18 from $20, reiterated at Buy and said, OCUL shares have been under pressure following SOL-1 topline data (see 2/17/26 note for recap), despite meeting key endpts. $REGN $EYPT $RHHBY KOD $SRZN Needham went on to say: Weakness was driven by a narrower-than-expected efficacy gap (~18%Δ) on vision maintenance due to an Eylea outperformance, as well as incidents of (mostly minor) AEs. SOL-1 results came short of investor expectations, but should still support FDA approval with a superiority label vs. Eylea with data supporting Q6M-Q12M dosing. These are key differentiating attributes vs. current pdts and those in development that should facilitate wide usage of Axpaxli. We view the recent valuation reset, which began prior to SOL-1 results, as overdone, and maintain our Buy rating and adjust our $ PT to $18 (from $20) to account for slightly lower Axpaxli peak sales.
1 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 19 at 2:18 PM
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development $OTLC $DNLI $RHHBY $ALNY $WVE https://ibn.fm/sRoMP
0 · Reply
Quantumup
Quantumup Feb. 19 at 1:38 PM
Cantor🏁 $SRZN Overweight/$40 $EYPT $OCUL $REGN $RHHBY KOD FDMT Cantor said: We are initiating coverage of SRZN at Overweight with a $40 price target. SRZN is a leader in Wnt biology, with foundational IP based on early work developing Wnt agonists and more recently advancing complex molecules towards the clinic in retinal diseases (Wnt/VEGF and Wnt/VEGF/IL-6 multi-functional molecules). SZN-8141 in both DME (PoS: 35%) and nAMD (PoS 20%). At a net price comparable with precedent VEGF products (~$14.5K per year), the resulting peak global probability-adjusted net sales are $895M for DME ($2.6B unadjusted) and $614M for nAMD ($3.1B unadjusted). Our $40 price target is based on our DCF, which utilizes a 15% discount rate and 2% terminal growth rate. We use ~25M fully diluted shares in our DCF compared to~8.6M basic shares as of 3Q25. 25M includes shares from the 2nd tranche of the PIPE (expected by Oct 31 2026) and adjusts the number of PIPE warrants using treasury stock method.
0 · Reply
AItrad
AItrad Feb. 18 at 1:40 PM
$OCUL A lot of people here are missing the point. SOL1 hit its primary endpoint agreed upon with the FDA to have a SUPERIORITY label. It will get approved no matter what the Eylea did in the study. This is the important thing: THE VALUE OF A SUPERIOR LABEL IS PRICELESS IN MARKETING. The marketing is going to be relentless. Think about the amount of Vabysmo and Eylea HD commercials you see now. Why so many? because they work on the patients. If these same patients see a commercial for Axpali that says it is THE ONLY MEDICINE EVER FOUND TO BE SUPERIOR TO EYLEA. A NEXT GENERATION MEDICATION THAT IS BETTER! BASED ON A PHASE 3 CLINICAL TRIAL, they will DEMAND the drug. It doesn’t matter how the trial was designed, the patients don’t understand the nuances, they just want the SUPERIOR drug. $EYPT won’t have that, $REGN won’t have that, $RHHBY won’t have that label. Only $OCUL. This is worth more than anything.
6 · Reply
scotttrader213
scotttrader213 Feb. 17 at 2:29 PM
$RHHBY moving much higher.
0 · Reply
free2dream
free2dream Feb. 17 at 1:27 PM
$SRPT move to $25 this week is in play, the quarter will be in $400M range, I would not be surprised to next quarter to return to the usual $600M range. Earnings next week, $RHHBY should snatch this while sub $2B market cap. They can assign easily 300-500% premium $XBI
2 · Reply
Watchthosestocks
Watchthosestocks Feb. 16 at 10:30 PM
$OCUL These results cover a "first to market" treatment with dominance potential in the same market that $SNY, $RHHBY, $MRK, and $BAYRY are all trying to get into or improve on. OCUL has highly likely showing of dominance from the results given the study is specifically designed to show "superiority" and all indications are positive — from a Tuesday AM announcement time preset, along with the speed of result release (no extra time taken to sugar coat something bad), interesting new job postings relating to sales/new products, special arrangements with the FDA to ensure study success, offers already from SNY, and the study design itself-(it's either superior or not) If it wasn't superior, it's very likely they would report the data at this time and in this way Good luck tomorrow
0 · Reply
twincam
twincam Feb. 16 at 5:46 PM
$OCUL Takeout speculation around $OCUL remains in play into the catalyst window. Potential competitive bidders beyond Sanofi ($SNY) include Roche ($RHHBY), Merck ($MRK), and Bayer ($BAYRY) — all strategically aligned with retina pipeline expansion and patent-cycle offset needs. Emergence of a second bidder would likely trigger spread tightening, IV repricing, and takeover-premium expansion across the chain.
1 · Reply
DidYouReadThis
DidYouReadThis Feb. 15 at 7:06 PM
$RHHBY $PFE $BAYRY
0 · Reply
Fillorkill7
Fillorkill7 Feb. 13 at 3:03 PM
$RHHBY who saw on LinkedIn that Boris Zaitra linked $IMUX announcement? They will buy $IMUX. It makes sense given their distribution in their MS drug and is right up their playbook. $XBI
1 · Reply
Fillorkill7
Fillorkill7 Feb. 13 at 2:57 PM
$RHHBY will buy $IMUX as the patent for Ocrevus is expiring soon. $IMUX ENSURE will bring in more revenue than their current drug because its oral and easy to prescribe and deliver. It’s a 10bn opportunity for them as they already have distribution. $XBI
0 · Reply
Jumpman23
Jumpman23 Feb. 13 at 1:40 AM
$RHHBY breakout alert 🚨
0 · Reply
scotttrader213
scotttrader213 Feb. 13 at 1:21 AM
$RHHBY Last few days moving up steadily in a shifting market. Moving higher, towards 60
0 · Reply
clan
clan Feb. 11 at 3:13 PM
$MNKD Nintedanib DPI It's coming! For the good of all Mannkind! $RHHBY $UTHR $JNJ
0 · Reply
Quantumup
Quantumup Feb. 10 at 9:17 PM
Stifel🏁 $OLMA Buy-$48 and said, We are initiating coverage of Olema Pharmaceuticals (OLMA) with a Buy rating and $48 Target Price. $AZN $LLY $RHHBY $ARVN BBOT Our thesis centers on lead asset palazestrant, a potential best-in-class oral SERD/CERAN. Its optimal pharmacology allows for sustained 24/7 estrogen receptor (ER) antagonism, which we believe is critical to preventing pro-oncogenic gene expression. We conservatively model peak sales of $3.1B in 2035 and stress that endocrine therapy in ER+/HER2- could be a $20B+ global market opportunity with plenty of room for many big players.
0 · Reply
scotttrader213
scotttrader213 Feb. 7 at 7:53 PM
$RHHBY Pipeline (why investors still care) Roche has one of the deepest late-stage pipelines in big pharma, including: • Alzheimer’s (gantenerumab setback, but multiple follow-ons) • Obesity/metabolic (early but active after seeing what NVO/LLY did) • Oncology ADCs (antibody-drug conjugates — hot area) • Neurology & immunology expansions They’re spending aggressively to replace aging blockbusters, which is the main debate around the stock.
0 · Reply
scotttrader213
scotttrader213 Feb. 5 at 3:42 PM
$RHHBY in a sea of red and carnage $RHHBY is in the green zone..
0 · Reply
scotttrader213
scotttrader213 Feb. 5 at 1:14 PM
$RHHBY breaking out towards 60.00
0 · Reply
Quantumup
Quantumup Feb. 4 at 7:09 PM
Wolfe Research said in its $CELC (Outperform; PT $110) note: PersevERAing through an External Catalyst $RHHBY $RLAY $AZN $PFE NVS LLY Wolfe Research additionally said: We think investors should be careful when extrapolating giredestrant's prior success to persevERA as it is a more difficult trial to beat, even after acknowledging that giredestrant is a good drug. We'd be buyers of CELC on any weakness related to the external catalyst.
0 · Reply